NOT FOR DISTRIBUTION
Header cover image

Medicalsystem BiotechnologyLtd

Market Cap

CN¥7.9b

Last Updated

2021/04/17 09:17 UTC

Data Sources

Company Financials

Executive Summary

Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, sale, and service of medical diagnostic products in China. More Details


Snowflake Analysis

Fair value with mediocre balance sheet.

Share Price & News

How has Medicalsystem BiotechnologyLtd's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 300439 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 300439's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-5.3%

300439

-0.2%

CN Biotechs

-0.8%

CN Market


1 Year Return

44.7%

300439

33.0%

CN Biotechs

25.0%

CN Market

Return vs Industry: 300439 exceeded the CN Biotechs industry which returned 32.5% over the past year.

Return vs Market: 300439 exceeded the CN Market which returned 24.7% over the past year.


Shareholder returns

300439IndustryMarket
7 Day-5.3%-0.2%-0.8%
30 Day8.1%9.5%-0.08%
90 Day33.3%2.9%-5.3%
1 Year44.7%44.7%33.4%33.0%27.0%25.0%
3 Year1.7%0.09%85.6%82.7%29.1%22.8%
5 Year-12.1%-14.0%74.7%71.4%30.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is Medicalsystem BiotechnologyLtd's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medicalsystem BiotechnologyLtd undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 300439 (CN¥23.02) is trading below our estimate of fair value (CN¥153.59)

Significantly Below Fair Value: 300439 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 300439 is unprofitable, so we can't compare its PE Ratio to the CN Biotechs industry average.

PE vs Market: 300439 is unprofitable, so we can't compare its PE Ratio to the CN market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 300439's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 300439 is good value based on its PB Ratio (4.9x) compared to the CN Biotechs industry average (6.4x).


Future Growth

How is Medicalsystem BiotechnologyLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicalsystem BiotechnologyLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Medicalsystem BiotechnologyLtd performed over the past 5 years?

-41.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 300439 is currently unprofitable.

Growing Profit Margin: 300439 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 300439 is unprofitable, and losses have increased over the past 5 years at a rate of 41% per year.

Accelerating Growth: Unable to compare 300439's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300439 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.9%).


Return on Equity

High ROE: 300439 has a negative Return on Equity (-30.21%), as it is currently unprofitable.


Financial Health

How is Medicalsystem BiotechnologyLtd's financial position?


Financial Position Analysis

Short Term Liabilities: 300439's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥1.5B).

Long Term Liabilities: 300439's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥170.9M).


Debt to Equity History and Analysis

Debt Level: 300439's debt to equity ratio (60.7%) is considered high.

Reducing Debt: 300439's debt to equity ratio has increased from 1.3% to 60.7% over the past 5 years.

Debt Coverage: 300439's debt is well covered by operating cash flow (99.4%).

Interest Coverage: 300439 is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Dividend

What is Medicalsystem BiotechnologyLtd current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 300439's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 300439's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 300439's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 300439's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 300439 is not paying a notable dividend for the CN market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 300439's dividend in 3 years as they are not forecast to pay a notable one for the CN market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ji Hua Zou (41 yo)

no data

Tenure

Mr. Zou Ji Hua serves as General Manager of Medicalsystem Biotechnology Co., Ltd. Mr. Zou served as Production Department Deputy Director, Assistant to General Manager and Deputy General Manager at Medical...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.9%.


Top Shareholders

Company Information

Medicalsystem Biotechnology Co.,Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medicalsystem Biotechnology Co.,Ltd
  • Ticker: 300439
  • Exchange: SZSE
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥7.887b
  • Shares outstanding: 383.00m
  • Website: https://www.nb-medicalsystem.com

Number of Employees


Location

  • Medicalsystem Biotechnology Co.,Ltd
  • No. 299, Qiming South Road
  • Yinzhou
  • Ningbo
  • Zhejiang Province
  • China

Listings


Biography

Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, sale, and service of medical diagnostic products in China. The company offers vitro diagnostic, biochemical, blood ce...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 09:17
End of Day Share Price2021/04/16 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.